NCT01560780View on ClinicalTrials.gov

Prasugrel for Prevention of Early Saphenous Vein Graft Thrombosis

PHASE3CompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

February 1, 2013

Primary Completion Date

April 30, 2018

Study Completion Date

May 31, 2018

Conditions
Coronary Artery Bypass
Interventions
DRUG

Prasugrel

one 10 mg tablet by mouth daily

DRUG

Placebo

placebo similar in appearance to prasugrel

Trial Locations (4)

32608

North Florida/South Georgia Veterans Health System, Gainesville, FL, Gainesville

60611

Jesse Brown VA Medical Center Community-Based Outpatient Clinic Lake Side Divison, Chicago, IL, Chicago

75216

VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX, Dallas

94121

San Francisco VA Medical Center, San Francisco, CA, San Francisco

All Listed Sponsors
lead

VA Office of Research and Development

FED

NCT01560780 - Prasugrel for Prevention of Early Saphenous Vein Graft Thrombosis | Biotech Hunter | Biotech Hunter